<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; sales</title>
	<atom:link href="http://www.tapanray.in/tag/sales/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Growing Intricacies of Today’s Field Staff Role And The Path Ahead</title>
		<link>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=growing-intricacies-of-todays-field-staff-role-and-the-path-ahead</link>
		<comments>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/#comments</comments>
		<pubDate>Mon, 30 Jan 2023 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field. staff]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[hybridization]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intricacies]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[outsourcing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[pull]]></category>
		<category><![CDATA[Push]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10742</guid>
		<description><![CDATA[With a varying degree, and in various forms, a hybrid working model is now gaining greater acceptance of several top pharma companies, across the world, just as in many other industries. This trend gets echoed in an article of December 07, 2022, &#8230; <a href="http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/growing-intricacies-of-todays-field-staff-role-and-the-path-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>This New Engagement Model Garners Significant Rewards For Pharma</title>
		<link>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=this-new-engagement-model-garners-significant-rewards-for-pharma</link>
		<comments>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/#comments</comments>
		<pubDate>Mon, 28 Nov 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[content]]></category>
		<category><![CDATA[cyberspace]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[difference]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10731</guid>
		<description><![CDATA[Last year, on July 26, 2021, I wrote in this blog on gaining a competitive edge with Omnichannel pharma marketing Omnichannel pharma marketing. However, from several recent studies, it appears, it’s still remains in a nascent stage. Most players in the industry haven’t &#8230; <a href="http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/this-new-engagement-model-garners-significant-rewards-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Using Selling Simulator For New Drug Launch In The New Normal</title>
		<link>http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=using-selling-simulator-for-new-drug-launch-in-the-new-normal</link>
		<comments>http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 23 Aug 2021 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[doctos]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[marketer]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[simulation]]></category>
		<category><![CDATA[simulator]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unprecedented]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10574</guid>
		<description><![CDATA[The reverberation of unparalleled business disruptions in healthcare caused by Covid pandemic, extends across its value chain &#8211; from patients and families to clinicians and pharmaceutical companies. Consequently, even many diehards or staunchly tradition-bound pharma marketers were being prompted to reimagine their &#8230; <a href="http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?</title>
		<link>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shape-of-future-pharma-operations-emerging-a-pragmatic-outlook</link>
		<comments>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/#comments</comments>
		<pubDate>Mon, 12 Apr 2021 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Pragmatic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10468</guid>
		<description><![CDATA[Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, &#8230; <a href="http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creating A Unique Patient Experience By Listening To Patients Voice – An Imperative In The New Normal</title>
		<link>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal</link>
		<comments>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 Mar 2021 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers. Covid-19]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[measuring]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[old normal]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Voice]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10446</guid>
		<description><![CDATA[Acquiring deeper insight on the patient journey through a disease treatment process to create and enhance end-to-end patient experience, never assumed such critical importance, ever in the past. Without this realization, I reckon, even digitalization of any scale in the pharmaceutical &#8230; <a href="http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creating-a-unique-patient-experience-by-listening-to-patients-voice-an-imperative-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Challenges For Brand Launch Success In The New Normal</title>
		<link>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-challenges-for-brand-launch-success-in-the-new-normal</link>
		<comments>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 08 Feb 2021 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[orchestrators]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patient-centric]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pivotal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[primary care]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10407</guid>
		<description><![CDATA[The drug manufacturers’ life blood to drive business growth has always been successful new product launch. However, this task has always remained a tough challenge to crack, since last so many years for various reasons. According to McKinsey &#38; Company: “About two-thirds of drug &#8230; <a href="http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Not To Let Go This Never Before Opportunity To Reposition Itself</title>
		<link>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself</link>
		<comments>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/#comments</comments>
		<pubDate>Mon, 14 Dec 2020 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actionable]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[competitors]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[holistic]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[medical-marketing]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reposition]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[WHD]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10366</guid>
		<description><![CDATA[‘While the COVID-19 pandemic has placed unparalleled demands on modern healthcare systems, the industry’s response has vividly demonstrated its resilience and ability to bring innovations to market quickly.’ This appeared in the McKinsey &#38; Company article – ‘Healthcare innovation: Building on the gains &#8230; <a href="http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-not-to-let-go-this-never-before-opportunity-to-reposition-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Predictive Rather Than Reactive Pharma Strategy</title>
		<link>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-predictive-rather-than-reactive-pharma-strategy</link>
		<comments>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/#comments</comments>
		<pubDate>Mon, 15 Jun 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[first in class]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[proactive]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reactive]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value-based]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10126</guid>
		<description><![CDATA[Traditionally, pharmaceutical industry, across the world, is mostly reactive &#8211; rather than proactive or predictive in its strategic approach &#8211; spanning across all its business domains. A large number of pharma players &#8211; both innovators and generic drug makers, formulate &#8230; <a href="http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Changing Doctors’ Practice Dynamics With Covid-19 And Beyond</title>
		<link>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=changing-doctors-practice-dynamics-with-covid-19-and-beyond</link>
		<comments>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/#comments</comments>
		<pubDate>Mon, 11 May 2020 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[connected]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dynamic]]></category>
		<category><![CDATA[face-to-face]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[practice]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10067</guid>
		<description><![CDATA[Unexpectedly, the answer to an onerous question surfaced just around a year’s time. In my article on this blog, written on April 08, 2019, I raised a question &#8211; “Would ‘Connected Healthcare’ Catch Pharma Players Off-Guard?” Interestingly, an unexpected and abrupt turn of &#8230; <a href="http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Sales Post Covid-19 Lockdown</title>
		<link>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-post-covid-19-lockdown</link>
		<comments>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/#comments</comments>
		<pubDate>Mon, 04 May 2020 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[customer-centricity]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[habit]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[oldest]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[post Covid-19]]></category>
		<category><![CDATA[preferences]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[years]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10054</guid>
		<description><![CDATA[Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer&#8217;s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global &#8230; <a href="http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
